The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Ankylosing Spondylitis Resource Center
    • Gout Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Long-Term Safety of Baricitinib for RA

Long-Term Safety of Baricitinib for RA

December 14, 2020 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

ACR CONVERGENCE 2020—On May 31, 2018, the U.S. Food & Drug Administration (FDA) approved the oral, selective Janus kinase (JAK) 1/JAK 2 inhibitor, baricitinib, to treat adults with moderate to severe active rheumatoid arthritis for whom one or more tumor necrosis factor antagonists proved inadequate.1

You Might Also Like
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA
  • FDA Approves Baricitinib for RA Patients
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
Explore This Issue
January 2021
Also By This Author
  • Celltrion Accelerates U.S. Launch of Infliximab-dyyb, a Remicade Biosimilar

In November, an updated safety analysis was presented on the long-term use of baricitinib during ACR Convergence 2020. The study, from Winthrop et al., assessed safety using data from nine randomized clinical trials (phase 3: n=5; phase 2: n=3; phase 1b: n=1) and one long-term extension study.2

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

Data from all patients who received at least one dose of baricitinib through Sept. 1, 2019, were used to calculate an incidence rate per 100 patient-years of exposure, which was called the All-bari-RA analysis set. Incidence rates for deep vein thrombosis, pulmonary embolism, and deep vein thrombosis and/or pulmonary embolism were also calculated for patients in the All-bari-RA set who received 2 or 4 mg of baricitinib.

Major adverse cardiovascular events were adjudicated in the long-term extension study and the five phase 3 studies. The serious infections incidence rates were evaluated through week 24 in the phase 2 and 3 studies and the All-bari-RA analysis set. This analysis was stratified by age group: younger than 65 years and 65 years and older.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Within the All-bari-RA analysis set, events of interest were assessed over time in 48-month intervals. To account for the aging of patients, incidence rates for death and malignancy, excluding non-melanoma skin cancer, were standardized to the World Health Organization world population 2000–2025 within each time interval.

Results
Data were analyzed for baricitinib-treated patients (n=3,770) representing 13,148 patient-years of exposure, with a median of 4.2 years of exposure to a maximum of 8.4 years of exposure per patient. The overall incidence ratios per 100 patient-years of exposure were 25.8 for treatment emergent adverse events and 7.2 for serious adverse events, including death.

In the All-bari-RA analysis set, the incidence rates of serious infections for patients younger than 65 years old was 2.1 (95% confidence interval [CI], 1.9–2.4) and for those 65 years and older was 4.8 (95% CI, 4.0–5.7). For major adverse cardiovascular events, deep vein thrombosis, pulmonary embolism, deep vein thrombosis and/or pulmonary embolism, and non-melanoma skin cancer, the incidence rates remained generally stable. After adjusting for age, no increases in the rates of death or malignancies, excluding non-melanoma skin cancer, were found. The incidence rates across the safety profiles were consistent with previous analyses.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

Pages: 1 2 | Single Page

Filed Under: ACR Convergence, DMARDs & Immunosuppressives, Drug Updates, Meeting Reports Tagged With: ACR Convergence 2020, baricitinib, JAK inhibitor, Rheumatoid Arthritis (RA)Issue: January 2021

You Might Also Like:
  • Long-Term Data Show Baricitinib Is Safe & Effective for RA
  • FDA Approves Baricitinib for RA Patients
  • FDA Staff Raises Safety Concerns Over Arthritis Drug Baricitinib
  • Baricitinib May Exhibit Better Efficacy Than Adalimumab for RA

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2021 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.